Site Tianjin, one of Novo Nordisk's strategic global production sites, has achieved local production supply. As of December 2024, the company's "Clinical Research Strategic Cooperation Center ...

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn as the Wegovy (semalgutide) developer seeks a ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese pharmaceutical company The United Bio-Technology (Hengqin) Co., as it looks to ...

In its fourth quarter 2024 investor letter, Polen Global Growth Strategy emphasized stocks such as Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages in the research and development ...